Comparison of Halving the Irradiation Time or the Verteporfin Dose in Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Shiode, Yusuke; Morizane, Yuki; Kimura, Shuhei; Hosokawa, Mio; Kawata, Tetsuhiro; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio

doi:10.1097/iae.0000000000000621

Cited by 19 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Half-dose or half-fluence verteporfin photodynamic therapy (PDT) may contribute to shorten episode duration. 7 – 12 Oral treatment by mineralocorticoid-receptor (MR) antagonists has also shown beneficial effects. 4 , 13 – 18 However, the ideal timing for these different interventions still remains to be determined.…”

mentioning

confidence: 99%

Acute Central Serous Chorioretinopathy

Daruich

Matet

Marchionno

et al. 2017

Retina

107

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Acute Central Serous Chorioretinopathy

Daruich

Matet

Marchionno

et al. 2017

Retina

107

View full text Add to dashboard Cite

show abstract

“…If fluid does not resolve spontaneously after 3 months for acute cases, 67% of the physicians recommend treatment with PDT. A combination of OCT, FA and ICGA is the preferred imaging modality used to determine the spot size for the PDT as reported by 82.4% of the specialists while reduced irradiation time and reduced verteporfin dose have been reported to be equally effective and safe in PDT for treating CSC,8 25 our survey results showed a practice preference in favour of full dose with half-fluence therapy.…”

Section: Discussionmentioning

confidence: 76%

Preferred practice pattern in central serous chorioretinopathy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Shiode et al revealed that also halving the PDT irradiation time for treating patients with cCSC has led to similar clinical outcomes to adopting the half-dose PDT regimen [ 91 ]; these results were subsequently confirmed by Liu et al in another study [ 92 ].…”

Section: Photodynamic Therapy (Pdt)mentioning

confidence: 90%

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

et al. 2020

View full text Add to dashboard Cite

Central serous chorioretinopathy (CSC) is a common cause of visual impairment in patients generally aged 20 to 60 and it is characterized by acute or chronic neurosensory detachments of the retina. Although CSC resolves spontaneously in most cases, in some patients it may cause permanent visual impairment in the working population; for this reason, several approaches, including photodynamic therapy (PDT), subthreshold micropulse laser treatment and oral mineralocorticoid receptor antagonists, have been studied as first-line treatment options for CSC. To date, half-dose PDT has provided the most encouraging results in this regard, supported by large, multicenter, randomized clinical trials such as the “Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy” (PLACE) trial; however, the role of novel possible non-invasive treatment options is attracting interest. This review article aims to discuss the current pharmacological treatment options investigated for the management of CSC, including aspirin, ketoconazole, beta blockers, rifampicin and many others. In particular, further evidence about oral mineralocorticoid receptor antagonists, firstly seen as promising non-invasive alternatives for treating CSC, will be provided and discussed in light of the recent “Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months” (VICI) trial results, which have largely resized their role as possible first-line oral treatment options for treating CSC.

show abstract

Comparison of Halving the Irradiation Time or the Verteporfin Dose in Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Abstract: Reduced irradiation time and reduced verteporfin dose were equally effective and safe in photodynamic therapy for chronic central serous chorioretinopathy.

Cited by 19 publications

References 23 publications

Acute Central Serous Chorioretinopathy

Acute Central Serous Chorioretinopathy

Preferred practice pattern in central serous chorioretinopathy

Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: A Review

Contact Info

Product

Resources

About